Senior Immunogenicity & Bioanalysis Scientist - mRNA

Moderna; Oxford; On-site; GBP 60,000 - 95,000; Full time

Benefits offered by this job

Healthcare

Well-being resources

Family benefits

Paid time off

Job summary

Moderna Harwell in the UK is seeking a Scientist to join the Bioanalytical and Molecular Assays team. You will design and deliver immunogenicity and bioanalytical strategies to support regulated clinical programmes, working with multidisciplinary teams.

You will develop and qualify assays (ADA, nAb, PK/PD) using ELISA, MSD and cell-based methods, helping expand Moderna's internal capabilities while adhering to GCP and regulatory expectations.

Qualifications

• PhD with 3+ years or MSc with 5+ years in bioanalytical method development and analysis.
• Strong knowledge of GCP and regulatory expectations in bioanalytics.
• Experience with ADA, nAb, PK/PD assays and related platforms.

Responsibilities

• Design and execute phase-appropriate bioanalytical strategies for regulated programmes.
• Lead development of ADA and neutralising antibody assays alongside PK/PD assays.
• Ensure assays are developed, qualified and validated within timelines and regs.
• Develop and optimise ELISA, MSD, cell culture and immunoblotting workflows.
• Support expansion of internal bioanalytical capabilities for the growing portfolio.
• Maintain SOPs and manage critical reagents to ensure robust performance.
• Collaborate with cross-functional teams to define sample journeys and study manuals.

Skills

Bioanalysis expertise

Regulatory awareness

Attention to detail

Multidisciplinary collaboration

Education

PhD in relevant field

MSc in relevant field

Tools

ELISA

MSD

LIMS

eLNB

Job description

Moderna Harwell in the UK is seeking a Scientist to join the Bioanalytical and Molecular Assays team. You will design and deliver immunogenicity and bioanalytical strategies to support regulated clinical programmes, working with multidisciplinary teams.

You will develop and qualify assays (ADA, nAb, PK/PD) using ELISA, MSD and cell-based methods, helping expand Moderna's internal capabilities while adhering to GCP and regulatory expectations.